文献速递泌尿生殖技术与安全MRPETCT

快速(<30分钟)「一体化」全身MRI用于高危前列腺癌TNM分期:可行性与68Ga-PSMA-PET/CT对比

Fast (< 30 min) "All-in-One" whole-body MRI for TNM staging in high-risk prostate cancer (PCa): Feasibility and comparison to 68Ga-Prostate Specific Membrane Antigen (PSMA)-PET/CT.
PubMed 文献 · Eur J Radiol · 2025-03-13

研究纳入52例高危转移前列腺癌患者,构建快速「一体化」全身MRI方案(基于PI-RADS v2.1和MET-RADS-P的快速T2加权与扩散加权成像联合双参数前列腺评估),并与常规68Ga-PSMA-PET/CT(按PSMA-RADS 1.0判读)对比T、N、M分期。快速全身MRI对局部肿瘤T分期检出率87% vs PSMA-PET/CT 77%(p=0.063),PSMA-PET/CT检出更多淋巴结40% vs 29%(p=0.031),结外转移M1b检出无比例差异(p>0.999)。

要点

  • 快速全身MRI对局部肿瘤T分期检出率87% vs PSMA-PET/CT 77%,差异未达统计学显著(p=0.063)。
  • PSMA-PET/CT检出更多淋巴结(40% vs 29%,p=0.031),淋巴结中位短径5 mm。
  • 两种技术对结外转移M1b检出无比例差异(p>0.999),技术间一致性从良好到很好(AC1 0.68–0.96)。

核心结论

  • 快速(<30分钟)「一体化」全身MRI方案可融入临床常规,其对T2/T3分期的解剖学刻画优于68Ga-PSMA-PET/CT,远处转移检出率相似,但淋巴结转移检出率略低。

研究设计与样本

  • 52例高危转移前列腺癌患者接受快速「一体化」全身MRI(联合基于快速T2加权和扩散加权成像的双参数前列腺评估,遵循PI-RADS v2.1和MET-RADS-P指南),并与常规68Ga-PSMA-PET/CT(按PSMA-RADS 1.0判读)对比;采用Gwet AC1评估技术间分期一致性,精确检验评估阳性发现比例差异。

诊断标准与关键数值

  • 快速全身MRI对局部肿瘤T分期检出率87% vs PSMA-PET/CT 77%(p=0.063);PSMA-PET/CT淋巴结检出率40% vs 全身MRI 29%(p=0.031),淋巴结中位短轴5 mm;结外转移M1b检出无比例差异(p>0.999);技术间一致性AC1:T=0.86、EPE=0.89、N=0.79、M1a=0.68、M1b=0.93、M1c=0.96;寡转移患者PSMA-PET/CT检出11% vs 全身MRI 19%。

临床应用与阅片要点

  • 快速「一体化」全身MRI可提供优于68Ga-PSMA-PET/CT的T2/T3分期解剖学刻画,远处转移检出率相似,但淋巴结转移检出率略低,阅片时需注意淋巴结评估的差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Next-generation imaging techniques, including PSMA-PET/CT and whole-body MRI (WB-MRI), are disrupting the management of prostate cancer (PCa). This study aimed to build a fast "All-In-One" WB-MRI protocol and to compare it to 68Ga-PSMA-PET/CT for local (T), nodal (N), and distant staging (M1a, M1b, M1c).

METHODS: Fifty-two PCa patients at high-risk for metastases underwent a fast "All-in-One" WB-MRI (combining biparametric prostate assessment based on rapid T2-weighted and diffusion-weighted imaging (DWI) following the PI-RADS v2.1 guidelines and the MET-RADS-P guidelines). This WB-MRI prococol was compared to routinely performed PSMA-PET/CT read according to PSMA-RADS 1.0. Inter-technique agreement on staging and proportion differences in positive findings were assessed using Gwet's AC1 and Exact test.

RESULTS: Fast "All-in-One" WB-MRI better detected local tumors (T) (87 % vs 77 %, p = 0.063), while PSMA-PET/CT detected more nodes (40 % vs 29 %, p = 0.031) with a median small axis of 5 mm. No proportion difference was observed in the detection of extra nodal metastases (M1b) (p > 0.999). Inter-technique agreement ranged from good (AC1M1a = 0.68, AC1N = 0.79) to very good (AC1T = 0.86, AC1EPE = 0.89, AC1M1b = 0.93, AC1M1c = 0.96). Fewer oligometastatic patients were detected with PSMA-PET/CT (11 %) compared to WB-MRI (19 %).

CONCLUSION: A fast (<30 min) "All-In-One" WB-MRI protocol can be implemented in clinical routine. It provides better anatomical characterization of the T2/T3 stage than 68Ga-PSMA-PET/CT, similar distant metastasis detection rate, but slightly inferior detection rate of nodal metastases.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Nieuwenhove SV, Lhommel R, Pasoglou V, et al. Fast (< 30 min) "All-in-One" whole-body MRI for TNM staging in high-risk prostate cancer (PCa): Feasibility and comparison to 68Ga-Prostate Specific Membrane Antigen (PSMA)-PET/CT. Eur J Radiol. 2025. PMID: 40132471. doi:10.1016/j.ejrad.2025.112033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。